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Abstract
Background: The lysosphingolipid sphingosine 1-phosphate (S1P) is carried in the blood in association with
lipoproteins, predominantly high density lipoproteins (HDL). Emerging evidence suggests that many of the effects
of HDL on cardiovascular function may be attributable to its S1P cargo.
Methods: Here we have evaluated how levels of S1P and related sphingolipids in an HDL-containing fraction of
human serum correlate with occurrence of ischemic heart disease (IHD). To accomplish this we used liquid
chromatography-mass spectrometry to measure S1P levels in the HDL-containing fraction of serum (depleted of
LDL and VLDL) from 204 subjects in the Copenhagen City Heart Study (CCHS). The study group consisted of
individuals having high serum HDL cholesterol (HDL-C) (females:≥73.5 mg/dL; males:≥61.9 mg/dL) and verified IHD;
subjects with high HDL-C and no IHD; individuals with low HDL-C (females:≤38.7 mg/dL; males:≤34.1 mg/dL) and
IHD, and subjects with low HDL-C and no IHD.
Results: The results show a highly significant inverse relationship between the level of S1P in the HDL-containing
fraction of serum and the occurrence of IHD. Furthermore, an inverse relationship with IHD was also observed for
two other sphingolipids, dihydro-S1P and C24:1-ceramide, in the HDL-containing fraction of serum. Additionally, we
demonstrated that the amount of S1P on HDL correlates with the magnitude of HDL-induced endothelial cell
barrier signaling.
Conclusions: These findings indicate that compositional differences of sphingolipids in the HDL-containing fraction
of human serum are related to the occurrence of IHD, and may contribute to the putative protective role of HDL
in IHD.
Background
The lysosphingolipid, sphingosine 1-phosphate (S1P), is
a component of human plasma [1]. Approximately 65%
of the S1P in blood is associated with the lipoproteins
LDL, VLDL and HDL, with the majority of lipoprotein-
associated S1P (~85%) bound to HDL [2]. Findings from
a growing number of animal and in vitro studies suggest
that S1P is a mediator of many of the cardiovascular
effects of HDL, including its ability to promote vasodila-
tion, angiogenesis and endothelial barrier function, to
protect against ischemia/reperfusion injury and to inhi-
bit/reverse atherosclerosis [3,4]. These latter, potentially
cardioprotective, effects involve S1P-mediated suppres-
sion of various inflammatory processes, including the
reduction of endothelial expression of monocyte and
lymphocyte adhesion molecules and decreased recruit-
ment of polymorphonuclear cells to sites of myocardial
infarction [3,4]. The S1P-dependent enhancement of
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dioprotective considering that reduction in endothelial
barrier is a factor underlying post ischemic edema, the
recruitment and migration of monocytes as well as the
introduction of triglyceride rich lipoprotein particles
into the blood vessel intima [6].
Epidemiological data from the Framingham Heart
Study [7,8] and other prospective studies [9] demon-
strate that high levels of HDL cholesterol (HDL-C) in
blood are inversely associated with risk for cardiovascu-
lar disease. However, some individuals with high HDL-C
and normal LDL cholesterol (LDL-C) still develop cardi-
ovascular disease [10]. This has lead to the hypothesis
that the HDL in some individuals might be dysfunc-
tional as an anti-atherogenic agent or perhaps even
proatherogenic as a result of the HDL lipid content, par-
ticularly that of S1P. In the present study, we addressed
this hypothesis by measuring levels of S1P and related
sphingolipids in HDL-containing fractions of serum
from groups of individuals having either high or low
HDL-C, with or without occurrence of ischemic heart
disease (IHD).
Results
Inverse correlation of S1P, DH-S1P and C24:1-ceramide in
the HDL-containing fraction of serum with ischemic heart
disease
Subjects were categorized into four groups based on
having high or low HDL-C and the presence or absence
of IHD (Table 1). Serum from each subject was sub-
jected to dextran sulfate/MgCl2 precipitation to prepare
a serum fraction containing HDL but depleted of LDL
and other apoB-containing lipoproteins. Results of liquid
chromatography/mass spectrometry (LC-MS-MS) com-
position analysis of sphingolipids in HDL-containing
fractions are summarized in Table 2. The major sphin-
golipids associated with the HDL-containing fractions
were S1P, C24 ceramide and C24:1 ceramide. As com-
pared to total serum (Table 3), the HDL-containing
fraction contained ~76% of the S1P, 21% of the C24 cer-
amide and 20% of the C24:1 ceramide found in total
serum.
Statistical analysis of the LC-MS-MS data showed that
S1P and DH-S1P in HDL-containing serum fractions
were significantly lower (17% and 37% reduction, respec-
tively; p < 0.0001) in individuals with high HDL-C having
IHD as compared to individuals with high HDL-C having
no evidence of IHD (Figure 1A and 1B). Furthermore,
S1P and DH-S1P in HDL-containing fractions were sig-
nificantly lower (22% and 33% reduction, respectively;
p < 0.0001) in individuals with low HDL-C and having
IHD as compared to individuals with low HDL-C having
no evidence of IHD (Figure 1A and 1B).
The ability to correctly classify patients with and without
IHD by using levels of S1P and DH-S1P was assessed by
receiver operating characteristic (ROC) analysis (Figure 2).
S1P and DH-S1P levels in the HDL-containing fraction
were both found to discriminate subjects with IHD from
those without IHD better than would be expected by
chance alone, as characterized by the area under the
curves (0.756 for S1P and 0.773 for DH-S1P) (Figure 2).
Among the other sphingolipids analyzed in the HDL-
containing fractions from the CCHS subjects, C24:1-
ceramide levels were also significantly lower (p < 0.003) in
individuals with IHD as compared to their control groups
for both the high and low HDL groups (Figure 1C).
Table 1 Characteristics of participants with and without IHD from the Copenhagen University Hospital and The
Copenhagen City Heart Study
With IHD No IHD
High HDL-C
(n= 53)
Group 1
Low HDL-C
(n= 42)
Group 2
High HDL-C
(n= 55)
Group 3
Low HDL-C
(n= 54)
Group 4
Age, years 63.1 ± 10.3 61.5 ± 9.3 62.6 ± 10.3 62.7 ± 9.6
Total cholesterol, mg/dL 208.1 ± 25.7 182.3 ± 29.4 207.3 ± 31.2 166.8 ± 31.1
High density lipoprotein-C, mg/dL 78.4 ± 14.3 32.4 ± 5.2 80.5 ± 14.1 33.6 ± 5.7
Low density lipoprotein-C, mg/dL 113.4 ± 26.3 120.9 ± 30.6 118.8 ± 28.0 117.7 ± 25.6
Triglycerides, mg/dL 82.1 ± 30.0 104.9 ± 31.1 74.1 ± 25.2 107.8 ± 29.4
Body mass index, kg/m
2 24.8 ± 4.2 26.0 ± 3.5 23.6 ± 3.1 28.0 ± 5.0
Smokers, % 27.1 26.8 42.6 33.3
Diabetes mellitus, % 7.7 14.3 5.5 7.4
All values are original measurements from the above-mentioned studies. Selection and matching for the present study were based on these values. All
individuals had LDL-C <160 mg/dL, triglycerides <150 mg/dL, and none were treated with LDL-C-lowering medications. Group 1: Females n = 16 Males n = 37;
Group 2: Females n = 13 Males n = 29; Group 3: Females n = 16 Males n = 39; Group 4: Females n = 15 Males n = 39. Group 1 had high HDL-C (>90th
percentile) and verified IHD; this group was compared with Group 3 without IHD, but matched by age, sex, and similar HDL-C levels (>90th percentile HDL-C
levels for Group 1 and 3 individuals were females:≥ 73.5 mg/dL; males:≥ 61.9 mg/dL). Group 2 had low HDL-C (<10th percentile) and verified IHD; this group was
compared with Group 4 without IHD, but matched by age, sex, and similar HDL-C levels (<10th percentile HDL-C levels for Group 2 and 4 individuals were
females:≤ 38.7 mg/dL; males:≤ 34.1 mg/dL). All individuals without IHD were selected from The Copenhagen City Heart Study’s 4th examination. Patients with
IHD were selected from individuals referred to the Copenhagen University Hospital, Rigshospitalet, Denmark for coronary angiography.
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Page 2 of 12Table 2 LC-MS-MS analysis of sphingolipid composition in HDL-containing fractions from CCHS serum samples
Sphingolipid
1 Concentration (nM)
High HDL-C, IHD
2 High HDL-C, No IHD
2 Low HDL-C, IHD
2 Low HDL-C, No IHD
2
Mean Std Mean Std P value
3 Mean Std Mean Std P value
3
S1P 1362.7 349.6 1643.4 256.2 <0.0001 1220.0 279.6 1569.1 357.0 <0.0001
Sph 10.4 8.5 BDL NA BDL BDL NA
DHSph BDL BDL NA BDL 9.9 22.9 NA
DH-S1P 95.4 49.1 150.5 42.1 <0.0001 82.1 38.1 122.3 45.5 <0.0001
C16-Cer 45.2 60.2 25.6 10.1 <0.0001 BDL 19.7 28.9 NA
DHC16-Cer 9.4 11.5 6.9 3.5 0.5122 BDL BDL NA
C14-Cer BDL BDL NA BDL BDL NA
C18:1-Cer 15.7 5.2 BDL NA BDL BDL NA
C18-Cer 42.2 14.4 41.8 15.9 0.9872 36.9 8.1 34.2 6.6 0.4587
C20:1-Cer 26.9 11.8 BDL NA BDL BDL NA
C20-Cer 103.6 52.3 94.9 37.4 0.8361 43.1 19.7 43.8 17.7 0.9542
C22-Cer 168.5 94.3 208.1 95.8 0.0999 65.4 39.6 79.9 47.7 0.2406
C20:4-Cer 10.1 4.0 BDL NA BDL BDL NA
C22:1-Cer 61.0 32.3 60.7 33.9 0.9851 19.2 8.0 24.9 9.1 0.0223
C24-Cer 1253.8 843.0 2008.3 858.6 <0.0001 708.2 309.9 785.8 392.2 0.8214
C24:1-Cer 699.1 437.5 912.4 348.8 0.0002 320.6 152.5 435.4 163.1 0.0027
C26-Cer 47.1 186.4 38.5 81.0 <0.0001 7.6 3.9 BDL NA
C26:1-Cer 36.5 106.3 27.1 16.2 0.0008 8.4 4.6 8.4 5.4 0.9629
1Abbrevations used: Sph, sphingosine; DH, dihydro; Cer, ceramide; P, phosphate; BDL, below detection limit, NA, not applicable since at least one group in the
pair was below detection limit.
2Sample sizes are High HDL-C, IHD, n = 53; High HDL-C, no IHD, n = 55; Low HDL-C, IHD, n = 42; Low HDL-C, no IHD, n = 54.
3p-values are derived from a Tukey’s comparison following a one-way ANOVA test conducted at level of significance 0.05.
Table 3 LC-MS-MS analysis of sphingolipid composition in total serum fractions from CCHS serum samples
Sphingolipid
1 Concentration (nM)
High HDL-C, IHD
2 High HDL-C, No IHD
2 Low HDL-C, IHD
2 Low HDL-C, No IHD
2
Mean Std Mean Std P value
3 Mean Std Mean Std P value
3
S1P 1889.9 546.0 1849.8 407.6 O-NS 1879.2 549.0 2053.0 628.0 O-NS
Sph BDL 22.3 11.0 NA 16.0 11.6 52.3 59.9 <0.0001
DHSph BDL 14.8 9.2 NA 10.1 5.1 16.6 11.6 <0.0001
DH-S1P 213.0 76.1 276.8 96.5 0.0032 273.9 98.2 271.3 106.0 0.9992
C16-Cer 171.4 70.7 212.0 86.8 0.0276 360.1 163.9 222.5 78.7 <0.0001
DHC16-Cer 139.1 74.9 60.1 38.5 <0.0001 77.1 39.7 75.5 31.6 0.9958
C14-Cer 54.6 8.9 92.3 19.7 <0.0001 117.0 34.4 103.0 35.1 0.0412
C-18:1-Cer 91.6 33.3 49.5 13.5 <0.0001 63.7 25.6 65.2 13.6 0.5492
C18-Cer 163.8 51.0 123.9 42.3 0.0002 171.2 69.9 123.2 31.9 <0.0001
C20:1-Cer 57.5 38.5 17.4 6.1 <0.0001 28.4 15.4 25.0 9.7 0.9997
C20-Cer 481.1 205.9 249.9 94.2 <0.0001 320.9 153.3 270.8 120.0 0.3547
C22-Cer 1045.2 347.4 758.2 194.0 <0.0001 1116.0 420.3 915.4 317.9 0.0147
C20:4-Cer BDL BDL NA BDL 6.7 10.1 NA
C22:1-Cer 128.7 118.9 62.3 37.3 0.0061 206.5 160.1 61.4 47.9 <0.0001
C24-Cer 6026.3 1816.2 5522.0 1381.9 O-NS 5577.5 2080.1 5724.1 1715.1 O-NS
C24:1-Cer 3433.4 847.9 2424.3 545.8 <0.0001 2838.6 951.2 3223.2 688.7 0.0681
C26-Cer 40.7 32.8 33.8 15.7 O-NS 38.9 30.2 36.0 18.8 O-NS
C26:1-Cer 30.7 20.0 30.8 11.9 0.8093 40.3 21.2 29.8 15.9 0.0140
1Abbrevations used: Sph, sphingosine; DH, dihydro; Cer, ceramide; P, phosphate; BDL, below detection limit; O-NS, Overall not significant by ANOVA; NA, not
applicable since at least one group in the pair was below detection limit.
2Sample sizes are High HDL-C, IHD, n = 53; High HDL-C, no IHD, n = 55; Low HDL-C, IHD, n = 42; Low HDL-C, no IHD, n = 54.
3p-values are derived from a Tukey’s comparison following a one-way ANOVA test conducted at level of significance 0.05.
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Page 3 of 12Figure 1 An inverse correlation exists between the occurrence of IHD and levels of S1P and DH-S1P in HDL-containing fractions from
CCHS subject serum. S1P (A) DH-S1P (B) and C24.1 ceramide (C) levels were measured by blinded LC-MS-MS analysis of 55 HDL-containing
preparations from CCHS individuals with high HDL-C and no evidence of IHD, 53 samples from individuals with high HDL-C and evidence of
IHD, 54 samples from individuals with low HDL-C and no evidence of IHD and 42 samples from individuals with low HDL-C and evidence of
IHD. In D-F, levels of S1P and DH-S1P in HDL-containing serum fractions from CCHS individuals with and without IHD are assessed relative to
apoA-I content. Levels of apoA-I in samples were quantified by immunoturbidometric assay using a Cobas Fara analyzer. Indicated p-values are
derived from a Tukey’s comparison following a one-way ANOVA test conducted at level of significance 0.05. Data are presented in box-and-
whisker diagrams. For the box-and-whisker diagrams, the boxes correspond to the interquartile range (IQR). The horizontal bar within the box is
drawn at the height of the median. The whiskers indicate the range of the data within 1.5 X IQR with outliers indicated as circles.
Figure 2 Receiver operating characteristic (ROC) curves for the ability of S1P and DH-S1P to distinguish between subjects with and
without IHD. Smaller values of the corresponding measure indicate stronger evidence for the presence of IHD. ROC curves were constructed
using SPSS v16.
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Page 4 of 12S1P, DH-S1P and C24:1-ceramide levels in the HDL-
containing fractions were also assessed relative to the
concentration of apolipoprotein A-I (apoA-I) in the
samples. The ratios of these sphingolipids to apoA-I
were all significantly lower (p ≤ 0.001) in individuals
with high HDL-C having IHD as compared to indivi-
duals with high HDL-C having no evidence of IHD
(Figure 1D-F). Furthermore, these ratios were also sig-
nificantly lower (p ≤ 0.006) in samples from individuals
with low HDL-C and having IHD as compared to indivi-
duals with low HDL-C having no evidence of IHD
(Figure 1D-F).
The proportion of subjects with IHD decreases as [S1P]
and [DH-S1P] increase
To examine the quantitative relationship of the concen-
tration of these lysosphingolipids associated with the
HDL-containing fraction and IHD, subjects were grouped
as shown in Table 4 by their quartile of [S1P] in the
HDL-containing fraction of serum (upper limits for Q1 =
1.21, Q2 = 1.45, Q3 = 1.73, Q4 = 2.38 μM). A Cochran-
Armitage test for linear trend was conducted to deter-
mine whether an increase in [S1P] corresponded to a
decrease in the proportion of subjects with IHD. The
result was statistically significant (Z = 6.0887, p-value
< 0.0001), indicating that the proportion of subjects with
IHD decreases as [S1P] (as defined by the corresponding
quartile) increases. The analysis was repeated using quar-
tiles of [DH-S1P] (upper limits for Q1 = 0.075, Q2 =
0.113, Q3 = 0.149, Q4 = 0.244 μM) (Table 5). The result
of the Cochran-Armitage test of these data was also
highly statistically significant (Z = 6.4654, p-value
< 0.0001), indicating that the proportion of subjects with
IHD decreases as [DH-S1P] (as defined by the corre-
sponding quartile) increases.
Analysis of sphingolipids in total serum samples
Sphingolipids in total serum from the CCHS subjects
were also evaluated. As shown in Table 3, levels of S1P
in total serum were not significantly different between
IHD and non IHD individuals for either the high HDL-
C or low HDL-C groups. Among the other sphingolipids
analyzed in total serum, C18-Cer, C22-Cer and C22:1-
Cer were significantly higher in the total serum from
individuals with IHD as compared to individuals without
IHD irrespective of their HDL levels (Table 3). Levels of
several other sphingolipids were statistically different
between IHD and non IHD individuals in the high
HDL-C and low HDL-C groups, but the direction of the
difference was opposite between the two groups.
DH-S1P enhances endothelial barrier activity in an S1P1-
dependent manner
While the effects of S1P on endothelial cell functions
have been implicated as a basis for the anti-atherogenic
effects of HDL, rather little is known as to the effects of
DH-S1P on vascular cell behaviors. Generally, DH-S1P
has been found to be an agonist of S1P receptors
[11-13]. We used electrical cell substrate impedance
sensing (ECIS) to assess the ability of DH-S1P to influ-
ence endothelial barrier activity, a major physiological
function of the endothelium. DH-S1P (on an albumin
carrier) induced a dose-dependent increase in transen-
dothelial electrical resistance (TEER) (Figure 3A). The
magnitude of the response was similar to that achieved
using S1P (Figure 3B). By contrast, C24:1-ceramide, the
third sphingolipid found to be significantly lower in
HDL-containing fractions of serum from individuals
with IHD, did not effect TEER (Additional file 1, Figure
S1).
We next evaluated the effects of S1P1 receptor
antagonists on the process of DH-S1P-induced barrier
enhancement. The S1P1 antagonist, W146, and the
S1P1/S1P3 antagonist, VPC23019, both inhibited the
TEER response to DH-S1P, similar to the inhibitory
effects these agents exert on S1P-mediated barrier
enhancement (Figure 3C and 3D). ECIS analyses were
also used to evaluate the effect of DH-S1P on endothe-
lial cell migration. The results showed that DH-S1P also
promoted S1P1-dependent endothelial cell migration
(Figure 4).
Enrichment of HDL with S1P elicits a dose dependent
enhancement of endothelial barrier function
Findings from the LC-MS-MS analysis of samples from
subjects with and without IHD suggested that S1P and
DH-S1P levels on HDL particles might relate to the bio-
logical activity of HDL in the context of its anti-athero-
genic effects. To address this we evaluated the effect of
HDL enriched with varying amounts of S1P on endothe-
lial cell barrier function. Transendothelial electrical
resistance monitoring showed that HDL enriched with
S1P elicited a dose dependent increase in maximal
Table 4 Contingency table of [S1P] quartiles and IHD
status
Quartile [S1P], μM Percentage of
Subjects (n)
Number of
Subjects
No IHD IHD
1 0.764 < [S1P] ≤
1.206
21.6
(11)
78.4
(40)
51
2 1.206 < [S1P] ≤
1.451
51.0
(26)
49.0
(25)
51
3 1.451 < [S1P] ≤
1.731
58.8
(30)
41.2
(21)
51
4 1.731 < [S1P] ≤
2.376
82.4
(42)
17.7 (9) 51
Totals 109 95 204
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than native HDL (Figure 5). These results are consistent
with the possibility that subjects with higher levels of
HDL-associated S1P might have lower vascular perme-
ability, which would be expected to decrease their sus-
ceptibility to atherosclerosis.
Discussion
This study was undertaken to test whether differences in
sphingolipid content of HDL might relate to the puta-
tive protective role of HDL in IHD. The findings indi-
cate that levels of S1P, DH-S1P and C24:1-ceramide in
the HDL-containing fraction of serum are inversely
related to the occurrence of IHD. This inverse relation-
ship was found to exist regardless of whether the
patients had high or low HDL-C levels. As an evidence
of the potential functional significance of these findings
we demonstrated that endothelial barrier response is
sensitive to the levels of HDL-associated S1P. Alteration
in endothelial barrier function is a critical factor under-
lying post ischemic edema, recruitment and migration
of monocytes, and introduction of triglyceride rich lipo-
protein particles into the intima of blood vessels [6,14].
Thus, our findings support the hypothesis that the
atheroprotective activity of HDL is at least in part a
function of S1P content, with higher levels being
protective.
Our findings raise a number of questions that require
further investigation. First, our studies do not precisely
define the blood carrier of S1P or DH-S1P important
for the IHD correlation that we have observed. While
the dextran sulfate/MgCl2 precipitation procedure that
we employed effectively removes LDL and other apoB-
containing lipoproteins, but not HDL from the serum, it
also does not remove albumin, a known blood carrier of
S1P [2]. Epidemiological studies have shown that a
highly significant inverse relationship exists between
serum albumin levels and risk of coronary heart disease
[15]. Furthermore, most of the putative cardioprotective
effects reported for S1P have been experimentally demon-
strated using albumin as the S1P carrier [3,5]. Thus, there
is a future need to establish whether HDL-S1P and/or
albumin-S1P levels in blood correlate inversely with occur-
rence of IHD. In this regard, it is important to point out
that the effect of HDL-associated S1P on barrier function
has been shown to persist longer than an equimolar dose
of albumin-associated S1P [5] as well as the fact that HDL
carries the majority of blood borne S1P (~55%) [2].
T h eo b s e r v e dv a l u e so fS 1 Pi ns e r u ma n dH D L - c o n -
taining fractions of CCHS samples (from subjects with
and without IHD) are generally higher than serum values
reported in the literature, which range from 484 ± 82
pmol/ml [1] to 1035 ± 26.4 pmol/ml [16]. It is possible
that erythrocyte hemolysis might have contributed to the
elevated level of S1P, since red cells contain stores of S1P
[17,18]. However, there was no overt evidence that red
cell hemolysis had occurred during the process of blood
collection and serum preparation. Despite the fact that
the measured S1P values were generally high in the
CCHS samples, the interpretations made in the present
study are in agreement with findings from a recent report
by Sattler et al. [19] showing that the amount of S1P in
isolated HDL was lower in subjects with stable coronary
artery disease as compared to controls.
While our analysis showed that an inverse correlation
existed between the occurrence of IHD and S1P levels
in the HDL-containing fraction (LDL and VLDL
depleted fraction), no significant correlation was
observed between S1P levels in total serum and the
occurrence of IHD. From these observations it follows
then that decreases in HDL-associated S1P in IHD sub-
jects are balanced by increases in S1P levels elsewhere,
perhaps in LDL and/or VLDL. If so it would be
expected that S1P levels in the LDL- and VLDL-con-
taining fraction of serum would correlate directly with
IHD in our study population. Despite the fact that total
serum S1P levels were not statistically different between
IHD and non-IHD subjects in our study we observed
that S1P was differentially partitioned in these groups.
In non IHD subjects, the HDL containing fraction had
82% of the S1P detected in total serum whereas IHD
subjects had only 69% of the S1P detected in total
serum (this data can be extracted from Tables 2 and 3).
This suggests that the mechanism controlling partition-
ing of S1P to HDL versus other lipoproteins is acting
differently between IHD and non IHD subjects.
Although our study did not detect a correlation
between S1P levels in total serum and IHD, another
Table 5 Contingency table of [DH-S1P] quartiles and IHD status
Quartile [DH-S1P], μM Percentage of Subjects (n) Number of Subjects
No IHD IHD
1 0.000 < [DH-S1P] ≤ 0.075 19.6 (10) 80.4 (41) 51
2 0. 075 < [DH-S1P] ≤ 0.113 45.1 (23) 54.9 (28) 51
3 0. 113 < [DH-S1P] ≤ 0.149 70.6 (36) 29.4 (15) 51
4 0.149 < [DH-S1P] ≤ 0. 244 78.4 (40) 21.6 (11) 51
Totals 109 95 204
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Page 6 of 12recent study showed a positive correlation between
serum S1P levels and coronary artery disease [16]. The
apparent disparity may relate to differences in the study
populations. In the study by Deutschman et al. [16],
61% of the subjects had elevated LDL-C and “the
average patient was taking three prescription drugs for
heart or circulatory problems, including b-blockers,
lipid-lowering agents, calcium blockers, nitrates, and
ACE inhibitors”. There is no indication of how these
drugs or concentration of LDL-C might influence S1P
Figure 3 DH-S1P enhances endothelial barrier in an S1P1 dependent manner. Confluent EC monolayers were grown under serum-free
conditions until a minimal TEER plateau was reached. In A, EC monolayers were incubated with varying concentrations of DH-S1P [111-1000
nM]. In B, EC monolayers were incubated with varying concentrations of S1P [111-1000 nM]. In C, EC monolayers were incubated with DH-S1P
[1000 nM] plus and minus the S1P1 antagonist W146 or the S1P1/S1P3 antagonist VPC23019 (each at 10 μM). In D, EC monolayers were
incubated with S1P [1000 nM] plus and minus the S1P1 antagonist W146 or the S1P1/S1P3 antagonist VPC23019 (each at 10 μM). Each of the
TEER tracings shown is an average from three independent experiments each with two replicates per condition. Impedance values were
normalized by dividing each value by the level of impedance measured just prior to the addition of effectors. As a control for A and B,
monolayers were treated with 40 μg/ml delipidated albumin (Control), a concentration corresponding to the amount of BSA carrier used for the
highest concentration of DH-S1P and S1P tested. As controls for C and D, ECs were treated with delipidated albumin-containing serum free
medium (SFM) plus vehicle buffer.
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their therapeutic benefit. Our subject population was
not receiving lipid-lowering drugs and had normal LDL-
C levels.
While there is much known about the bioactivities of
S1P, particularly in the context of vascular biology, rela-
tively little is known as to the biological actions of DH-
S1P and C24:1-ceramide, the other two sphingolipids
whose levels in the HDL-containing fraction inversely
correlate with the occurrence of IHD. Positive correla-
tions have been found between total plasma ceramide
levels and levels of total cholesterol and triglycerides [20],
well-known lipid risk factors of atherosclerosis [21-23].
While this may seem in opposition to our findings, it is
notable that 1) C24:1-ceramide is a specific subspecies of
ceramide, 2) our study population only included indivi-
duals displaying normal levels of total cholesterol and tri-
glycerides (Table 1), and 3) our measurements were
made on the HDL-containing fraction of serum, not total
plasma or serum. It is not clear how C24:1-ceramide
associated with HDL might influence the etiology of
IHD. There is no known cell surface receptor for C24:1-
ceramide; however, ceramide has been shown to be
transported through the action of the ATP-binding cas-
sette (ABC) transporter, ABCA7 [24], which effluxes
lipids to apoA-I [25]. This could account for the presence
of C24:1-ceramide on HDL, but how or whether this
C24:1-ceramide influences the bioactivities of HDL
remains to be determined. With respect to DH-S1P,
Figure 4 DH-S1P enhances endothelial cell motility in an S1P1 dependent manner. EC monolayers were wounded with a burst of high
electrical current as described previously [5] and the culture medium then supplemented with DH-S1P (1 μM) (A), or S1P (1 μM) (B) in the
presence or absence of the S1P1 antagonist W146 (10 μM in DMSO vehicle). The migration of cells into the wounded areas was measured in
real-time by electrical impedance. As a control in both experiments the medium was supplemented with delipidated BSA (Control) in PBS.
Electrical impedance data are normalized to baseline following wounding. The data depicted are representative of two independent experiments
and traces represent averages of two replicates per condition.
Figure 5 Levels of HDL-associated S1P dictate the magnitude
of the TEER response. Confluent EC monolayers were incubated
with native HDL (72 nM S1P) or HDL containing varying amounts of
exogenously added S1P. HDL was added to achieve a final
concentration of 250 μg protein/ml. As a control, monolayers were
incubated with the vehicle buffer, 0.03 mM EDTA in Dulbecco’s PBS
(Control). Each of the TEER tracings shown is an average from two
replicates per treatment. Impedance values were normalized by
dividing each value by the level of impedance measured just prior
to the addition of effectors. The results depicted are representative
of two independent experiments.
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influencing vascular cell processes. Here we show that
DH-S1P, like S1P, is a potent inducer of S1P1-dependent
endothelia cell barrier function and endothelial cell migra-
tion. These findings are consistent with reports that DH-
S1P acts as an S1P receptor agonist [11-13]. Other studies
have shown that DH-S1P can mediate induction of matrix
metalloproteinase 1 (MMP1) expression in dermal fibro-
blasts, a response not reproduced by S1P [26]. MMP1 is
believed to play an important role in the pathogenesis of
atherosclerosis. Findings from mouse studies indicate that
MMP1 can inhibit atherosclerosis [27], and recent human
studies show that persons homozygous for a transcription-
ally overactive allele of the MMP1 gene have a reduced
risk of coronary heart disease [28]. Thus, HDL with low
levels of DH-S1P might be less atheroprotective owing to
its reduced capacity to induce MMP1 expression.
Another potential implication from this study is that
the measurement of S1P and/or related sphingolipids
may have diagnostic value. Based on ROC analysis
(Figure 2), the sensitivity and specificity of S1P and DH-
S1P is similar to what has been previously described for
the use of routine lipid and lipoprotein markers for car-
diovascular risk assessment [29]. In the present study,
the subjects were matched for HDL-C levels, but S1P
and DH-S1P still differed between subjects with and
without IHD. While additional risk analyses on different
cohorts will need to be performed, the results from the
present study suggest that the S1P and DH-S1P content
of the HDL containing fraction may be helpful in identi-
fying individuals that are at increased risk of IHD
regardless of their HDL-C levels.
Conclusions
Our findings highlight the possibility that the effects of
lipoproteins on the etiology of cardiovascular disease
may be attributable, at least in part, to sphingolipid
composition of lipoproteins. At least one predominantly
HDL-associated sphingolipi d ,S 1 P ,i sw e l lk n o w nt oe l i -
cit an array of vascular responses, many of which can be
considered as cardioprotective. Furthermore, many of
the cardioprotective effects of HDL have been attributed
to its S1P cargo. Now through analysis of large numbers
of serum samples from human subjects, we have estab-
lished that levels of S1P and two other sphinoglipids in
the HDL-containing fraction of serum have highly sig-
nificant inverse correlations with the occurrence of IHD.
This is evidence that in addition to cholesterol, sphingo-
lipids may be risk factors for IHD as well as targets for
therapeutic intervention. If it is established that low
levels of HDL-associated sphingolipids are IHD risk
factors, then therapies that increase specific plasma
HDL-sphingolipid levels may hold promise for decreas-
ing the risk for IHD.
Methods
Study group
The study involved the analysis of blood serum samples
existing in the Copenhagen City Heart Study (CCHS)
collection [21,30] which includes a group of patients
with documented coronary atherosclerosis and IHD (the
Copenhagen Ischemic Heart Disease Study) [31,32]. The
CCHS is a prospective cardiopulmonary study of 20- to
93-year-old Danes of both sexes sampled from the gen-
eral population in 1976-1978 and reexamined in 1981-
1983, 1991-1994 and 2001-2003 [33]. Informed consent
was obtained from all participants. The Danish Ethics
Committees of Copenhagen and Frederiksberg approved
the study (study No. 100.2039/91 and KA93125). Based
on analysis of the total population (individuals from
CCHS without ischemic heart disease (IHD), n = 5,911
[women = 3,384; men = 2,527]) the average normal
level of HDL-C for women is 62.1 ± 18.9 mg/dL and
50.7 ± 16.4 mg/dL for men. Testing was performed on
four groups of CCHS samples, including 55 samples
from individuals with high HDL-C (80.3 ± 14.3 mg/dL)
and no evidence of IHD, 53 samples from gender and age
matched individuals with high HDL-C (78.8 ± 14.2 mg/dL)
and verified IHD, 54 samples from individuals with low
HDL-C (33.7 ± 5.8 mg/dL) and no evidence of IHD, and
42 samples from gender and age matched individuals
with low HDL-C (31.8 ± 5.3 mg/dL) and verified IHD.
All individuals had LDL-C <160 mg/dL, triglycerides
<150 mg/dL, and none were treated with LDL-C-
lowering medications. Subjects had an average age of 62
years, approximately 30% were women and 8.5% had dia-
betes mellitus. The characteristics of subjects from which
samples were derived are summarized in Table 1. Addi-
tional apolipoprotein and lipid information pertaining to
the same groups of subjects as analyzed herein is published
in a recent study [34]. This study also showed that for all
of the criteria described in Table 1, there was no statisti-
cally significant difference between individuals with and
without IHD for both the high and low HDL-C groups.
Sphingolipid analysis of CCHS serum samples
Blinded liquid chromatography-tandem mass spectrome-
try (LC-MS-MS) sphingolipid analysis was performed on
aliquots of total serum samples and on aliquots of LDL-
and VLDL-depleted, HDL-containing preparations from
CCHS serum samples. To prepare LDL- and VLDL-
depleted, HDL-containing preparations, CCHS serum
samples were subjected to magnetic bead-dextran-sul-
fate/MgCl2 precipitation (Reference Diagnostics, Inc.,
Bedford, MA) to remove apolipoprotein B (apoB)-con-
taining particles (i.e., LDL and VLDL) [35]. Total choles-
terol levels in the supernatants were measured by an
enzymatic method using a commercially available kit
(Wako Pure Chemical Co., Osaka, Japan). ApoA-I levels
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parations on a Cobas Fara analyzer (Roche Diagnostics
Systems, Inc) using reagents from Sigma Aldrich (St.
Louis, MO).
Aliquots of total serum or the LDL- and VLDL-
depleted, HDL-containing fractions were subjected to
LC-MS-MS analysis on a Thermo Finnigan TSQ 7000
triple quadrupole mass spectrometer, operating in a
Multiple Reaction Monitoring( M R M )p o s i t i v ei o n i z a -
tion mode, using a modified version of the protocol
described by Bielawski et al. [36]. Briefly, CCHS samples
(50 μl diluted 1:2 with Dulbecco’s phosphate-buffered
saline [DPBS]) were fortified with the internal standards
(ISs: C17 base D-erythro-sphingosine (17CSph), C17
S1P (17CS1P), N-palmitoyl-D-erythro-C13 sphingosine
(13C16-Cer) and heptadecanoyl-D-erythro-sphingosine
(C17-Cer)), and extracted with ethyl acetate/iso-propa-
nol/water (60/30/10 v/v) solvent system. After evapora-
tion and reconstitution in 100 μlo fm e t h a n o l ,s a m p l e s
were injected on the HP1100/TSQ 7000 LC/MS system
and gradient eluted from the BDS Hypersil C8, 150 ×
3.2 mm, 3 μmp a r t i c l es i z ec o l u m n ,w i t h1 . 0m M
methanolic ammonium formate/2 mM aqueous ammo-
nium formate mobile phase system. Peaks corresponding
to the target analytes and internal standards were col-
lected and processed using the Xcalibur software system.
Quantitative analysis was based on calibration curves
generated by spiking an artificial matrix with known
amounts of the target analyte synthetic standards and
an equal amount of the internal standards (ISs). The tar-
get analyte/IS peak areas ratios were plotted against ana-
lyte concentration. The target analyte/IS peak area ratios
from the samples were similarly normalized to their
respective ISs and compared to the calibration curves,
using a linear regression model.
Statistical analysis of data
A one-way ANOVA model was fit to each response in
order to look for differences in group means. The Stu-
dentized residuals were calculated and assessed for the
model assumptions of normality and constant variance.
Following a significant result, Tukey’s adjustment for
multiple comparisons was used to control the Type I
error rate associated with the corresponding pairwise
comparisons. Hypothesis tests were conducted at level
of significance 0.05.
S1P- and DH-S1P-fortification of HDL
HDL (1.063-1.21 g/ml density fraction) was purified
from human plasma by sodium bromide density-gradi-
ent centrifugation as described in Wasan et al. [37] and
dialyzed against DPBS, 0.03 mM EDTA. Following dialy-
sis, total cholesterol, LDL-C and HDL-C were deter-
mined using a lipid profile chip (Cholestech, Hayward,
CA). No LDL-C was detected in the purified HDL frac-
tion. Protein content of HDL was measured by Bio-Rad
DC assay (Bio-Rad, Hercules, CA). Sphingolipid content
of HDL was measured by LC-MS-MS by the MUSC
Lipidomics Core Facility according to previously
reported methods [5]. S1P- and DHS1P-fortified HDL
were prepared by preincubation of native HDL over-
night at 4°C with varying amounts of S1P or DH-S1P
(0-1.38 μg S1P/mg HDL protein) followed by dialysis
against DPBS, 0.03 mM EDTA to remove free sphingo-
lipds. Sphingolipid content of fortified HDL was mea-
sured by LC-MS-MS.
Transendothelial electrical resistance (TEER) assay
TEER was measured by electrical cell substrate impe-
dance sensing (ECIS) [38] as described previously [5].
Briefly, human umbilical vein endothelial cells (HUVEC)
(Cascade Biologics, Inc., Portland, OR) maintained in
EGM-2 medium were seeded into wells of ECIS 8W10E
+ electrode arrays at a density of 1 × 10
5 cells per well.
Arrays were pre-coated with human plasma fibronectin
(Invitrogen, Carlsbad, CA) at 100 μg/ml in 0.15 M
NaCl, 0.01 M Tris, pH 8.0. Cells were cultured in EGM-
2 medium and impedance measured every five min at
15 kHz frequency. When the electrical resistance
reached a maximal plateau (~3 days) the medium was
replaced with serum-free endothelial basal medium
(EBM; Lonza) containing 1X penicillin-streptomycin-
glutamine (Invitrogen). Electrical resistance was moni-
tored until a minimal plateau was reached (~24 h).
Effectors (i.e., S1P fortified-HDL, dihydro-S1P (DH-
S1P)-fortified HDL, S1P-albumin (fatty acid free bovine
serum albumin from Sigma), DH-S1P-albumin or albu-
min in DPBS) were introduced into the culture medium
by removing a volume corresponding to that of the
effector to be added. S1P (i.e., D-erythro-sphingosine-1-
phosphate) and DH-S1P (i.e., dihydro-D-erythro-sphin-
gosine-1-phosphate) were purchased from Avanti Polar
Lipids, Inc. (Alabaster, AL). The maximum volume of
each effector added did not exceed 1/25 of the 400 μl
volume of conditioned culture medium in each well. For
experiments evaluating the effects of the S1P1 antago-
nist W146 (Avanti Polar Lipids) and the S1P1/S1P3
antagonist VPC23019 (Avanti Polar Lipids) on TEER,
antagonist stocks (1 mM in 5% acidified DMSO, 4 mg/
ml BSA) were diluted 1:100 into the conditioned EBM
at the same time that S1P or HDL was added.
Additional material
Additional file 1: Evaluation of the effects of C24:1 ceramide on
endothelial barrier. Confluent endothelial cell (EC) monolayers were
grown under serum-free conditions until a minimal TEER plateau was
reached. EC monolayers were incubated with varying concentrations of
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Page 10 of 12C24:1 ceramide [333-3000 nM) or S1P [111 nM]. Each of the TEER
tracings shown is an average of two replicates per condition. Impedance
values were normalized by dividing each value by the level of
impedance measured just prior to the addition of effectors. As a control,
EC monolayers were treated with delipidated albumin (Control), a
concentration corresponding to the amount of BSA carrier used for the
highest concentration of C24:1 ceramide tested.
List of abbreviations used
S1P: sphingosine 1-phosphate; DH-S1P: dihydro sphingosine 1-phosphate,
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